[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-naphtbalen-2-yl-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-phenyl]-naphtbalen-2-yl-amine
• 英文别名: N-[3-(4-bromo-2-methylpyrazol-3-yl)phenyl]naphthalen-2-amine
• 化学式: C₂₀H₁₆BrN₃
• 分子量: 378.271
• InChiKey: AQNDRNPLMCDGDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] DIARYLAMINE AND ARYLHETEROARYLAMINE PYRAZOLE DERIVATIVES AS MODULATORS OF 5HT2A<br/>[FR] DERIVES DU PYRAZOLE DIARYLAMINE ET DU PYRAZOLE ARYLHETEROARYLAMINE MODULATEURS DU 5HT2A
  申请人：ARENA PHARM INC

  公开号：WO2004058722A1

  公开（公告）日：2004-07-15

  One aspect of the present invention relates to certain diarylamine and arylheteroarylamine pyrazole derivatives of Formula (A) and pharmaceutical compositions that modulate the activity of the human 5HT2A serotonin receptor. Compounds and pharmaceutical compositions are directed to methods useful in the prophylaxis or treatment of reducing platelet aggreagation, sleep disorders, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia and NOS schizophrenia and related disorders. Another aspect of the present invention is directed to the method of prophylaxis or treatment of 5HT2A serotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered separately or together.

  本发明的一个方面涉及某些Formula（A）的二芳基胺和芳基杂芳基胺吡唑衍生物以及调节人类5HT2A 5-羟色胺受体活性的药物组合物。化合物和药物组合物用于预防或治疗减少血小板聚集、睡眠障碍、冠状动脉疾病、心肌梗死、短暂性缺血性发作、心绞痛、中风、心房颤动、减少血凝块形成风险、哮喘或其症状、激动或症状、行为障碍、药物诱导的精神病、兴奋性精神病、吉尔·德·拉·图雷特综合征、躁狂障碍、器质性或NOS精神病、精神病性障碍、精神病、急性精神分裂症、慢性精神分裂症和NOS精神分裂症及相关疾病的方法。本发明的另一个方面涉及与多巴胺D2受体拮抗剂（如氟哌啶）联合使用的5HT2A 5-羟色胺受体介导的疾病的预防或治疗方法，分别或合并给药。
• Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
  申请人：Teegarden Bradley

  公开号：US20060229335A1

  公开（公告）日：2006-10-12

  One aspect of the present invention relates to certain diarylamine and arylheteroarylamine pyrazole derivatives of Formula (A) and pharmaceutical compositions that modulate the activity of the human 5HT2A serotonin receptor. Compounds and pharmaceutical compositions are directed to methods useful in the prophylaxis or treatment of reducing platelet aggreagation, sleep disorders, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia and NOS schizophrenia and related disorders. Another aspect of the present invention is directed to the method of prophylaxis or treatment of 5HT2A serotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered separately or together.

  本发明的一个方面涉及公式（A）的某些二芳基胺和芳基杂环胺吡唑衍生物以及调节人类5HT2A 5-羟色胺受体活性的制药组合物。这些化合物和制药组合物适用于预防或治疗降低血小板聚集、睡眠障碍、冠状动脉疾病、心肌梗塞、短暂性脑缺血发作、心绞痛、中风、房颤、减少血栓形成风险、哮喘或其症状、激动或症状、行为障碍、药物诱导性精神病、兴奋性精神病、Gilles de la Tourette综合征、躁狂障碍、有机或NOS精神病、精神障碍、急性精神分裂症、慢性精神分裂症和NOS精神分裂症及相关疾病的有用方法。本发明的另一个方面是在与多巴胺D2受体拮抗剂（如氟哌利多）组合使用的情况下，预防或治疗5HT2A 5-羟色胺受体介导的疾病的方法，分别或同时给药。